3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Conditions
Thoracic Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Neoplasms, Nerve Tissue
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lung Neoplasms
1
Lung Diseases
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Bronchogenic
1
Carcinoma
1
Bronchial Diseases
1
Adenocarcinoma
1
Interventions
Cisplatin
30
Radiotherapy
24
pembrolizumab
21
Cetuximab
21
Docetaxel
13
Fluorouracil
12
Radiotherapy, Intensity-Modulated
10
Paclitaxel
9
Radiation
8
Nivolumab
7
Everolimus
7
Carboplatin
7
Oxaliplatin
6
Gemcitabine
5
Surgical Procedures, Operative
4
Radiosurgery
4
Magnetic Resonance Spectroscopy
4
Gefitinib
4
Erlotinib Hydrochloride
4
Amifostine
4
Pemetrexed
3
Filgrastim
3
Capecitabine
3
Bleomycin
3
Biopsy
3
zalutumumab
2
spartalizumab
2
pegfilgrastim
2
niraparib
2
durvalumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Head and Neck Neoplasms
×
pralsetinib
×
Clear all
NCT04222972
2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3
Terminated
223 enrolled
18 charts